FDA Grants First Approval to First-Line Therapy for Advanced Anal Cancer
MedPage Today) — The FDA granted a first-ever approval for a first-line therapy for anal cancer to the PD-1 inhibitor retifanlimab (Zynyz), the agency announced Thursday. The approval stipulates use in combination with carboplatin and paclitaxel…
MedPage Today) — The FDA granted a first-ever approval for a first-line therapy for anal cancer to the PD-1 inhibitor retifanlimab (Zynyz), the agency announced Thursday.
The approval stipulates use in combination with carboplatin and paclitaxel…
Read More
About Author
